Spanish study of quality of life in migraine (II). Profile of consumption of medications and subjective efficacy;Estudio espanol de calidad de vida en la migrana (II). Patron de consumo de farmacos y eficacia subjetiva

Neurologia

Volumn 14, Issue 5, 1999, Pages 204-209

  Pascual, J ^a   Leira, R ^b   Lainez J M ^c   Alberca, R ^d   Titus, F ^e   Morales, F ^f   Diez Tejedor E ^g   Garcia De Polavieja J ^h  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c Hospital General de Valencia   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h Policlínica de Especialidades CMH   (Spain)

Author keywords

Migraine; Preventive treatment; Symptomatic treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CODEINE; DIPYRONE; ERGOT ALKALOID; IBUPROFEN; KETOPROFEN; KETOROLAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SUMATRIPTAN; VALPROIC ACID; ANTIDEPRESSANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; SEROTONIN AGONIST;

ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; PALLIATIVE THERAPY; PRESCRIPTION; PROPHYLAXIS; QUALITY OF LIFE; CLINICAL TRIAL; MULTICENTER STUDY; REVIEW; SPAIN; TREATMENT OUTCOME;

ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; HUMANS; MIGRAINE DISORDERS; QUALITY OF LIFE; SEROTONIN AGONISTS; SPAIN; TREATMENT OUTCOME;

EID: 0033061165     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Pascual J, Combarros O, Leno C, Polo JM, Rebollo M, Berciano J. Distribución por diagnósticos del dolor de cabeza como motivo de consulta neurológica. Med Clin (Barc) 1995; 104: 161-164.
2. Gracia-Naya M, Marta E, Usón M, Carod J. Estudio epidemiológico descriptivo de una consulta externa de Neurología. Rev Neurol 1996; 24: 633-637.
3. Gracia-Naya M, Usón-Martín MM. Grupo de estudio de neurólogos aragoneses. Rev Neurol 1997; 25: 194-199.
4. Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well'being of patients with migraine headache. Headache 1994; 34: 337-343.
5. Láinez JM. Migraña y calidad de vida. Neurología 1998; 13 (Supl 2): 1-8.
6. Leira R, Díez-Tejedor E, Láinez JM, Pascual J, editores. Actitud diagnóstica y terapéutica en la cefalea. Madrid: Ediciones Ergón, 1997.
7. Silberstein SD. Preventive treatment of migraine: an overview. Cephalalgia 1997; 17: 67-72.
8. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992; 12: 81-84.
9. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994; 44: 647-651.
10. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52: 281-286.
11. Leira R, Láinez JM, Pascual J, Díez-Tejedor E, Morales F, Titus F et al. Estudio español de calidad de vida en migraña (I). Perfil del paciente con migraña que acude a consultas de neurología. Neurología 1998; 13: 287-291.
12. Headache Classification Committee of the Internacional Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 (Supl 7): 1-95.
13. Ferrari M. Migraine. Lancet 1998; 351: 1.043-1.051.
14. Pascual J. Sumatriptán. Neurología 1994; 8: 352-357.
15. Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan in the acute treatment of migraine. Eur Neurol 1991; 31: 314-322.
16. Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine: Eur Neurol 1992; 32: 177-184.
17. Tfelt-Hansen P, Henry P, Mulder K, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicilate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346: 923-926.
18. Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53: 180-184.
19. Goadsby PJ. A triptan too far? J Neurol Neurosurg Psychiatry 1998; 64: 143-147.
20. Tfelt-Hansen P, Dahlof C, Pascual J, Láinez JM, Henry P, Diener HC et al. Ergotamine: current place in the treatment of acute migraine attacks. A European consensus brain, sometido.
21. Tfelt-Hansen P, Shanks RG. Beta-adrenoceptor blocking drugs. En: Olesen J, Tfelt-Hansen P, Welch KMA, editores. The headaches. Nueva York: Raven Press, 1993; 363-372.